PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. METHODS: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. RESULTS: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade. CONCLUSIONS: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some of these models, resistance can be overcome by including CDK4/6 inhibitors in the treatment (Finn et al., 2009; Goel et al., 2016; Kwong et al., 2012; Vora et al., 2014; Zhou et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2009
In the citing paper
“Preclinical data utilizing palbociclib demonstrated the substantial sensitivity of hormone receptor (HR)-positive cell lines, compared to HR-negative cell lines, in part related to a higher incidence of RB-negativity in the latter breast cancer subgroup (81).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Multiple drug effect analysis was performed using computer software as previously described [33].”
MethodA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Research works printed but not linked: 1
- Duchnowska RJJ Thorat MA Morimiya A Sledge GW Li L Biernat W Szczylik C Steeg PS Badve SS Gene expression analysis for prediciton of early brain metastasis in HER2-positive breast cancer patients [abstract 1019] J Clin Oncol 2008 26 20 Suppl abstract 1019
Cited by
Items 201–300 of 1,000
Onesti, C. E., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1852934 · Cited by 127
Pan-cancer proteogenomics connects oncogenic drivers to functional states
Li, Y., Porta‐Pardo, E., Tokheim, C. J., Bailey, M. H., Yaron, T. M., Stathias, V., Geffen, Y., Imbach, K. J., Cao, S., Anand, S. K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.014 · Cited by 136
Ihnen, M., zu Eulenburg, C., Kolarova, T. R., Qi, J. W., Manivong, K., Chalukya, M., Dering, J., Anderson, L. A., Ginther, C., Meuter, A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0813 · Cited by 114
Targeting the Checkpoint to Kill Cancer Cells
Benada, J., & Macůrek, L. (2015) · Biomolecules · doi:10.3390/biom5031912 · Cited by 124
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
Traina, T., Cadoo, K., & Gucalp, A. (2014) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s46725 · Cited by 107
Malorni, L., Curigliano, G., Minisini, A. M., Cinieri, S., Tondini, C. A., D’Hollander, K., Arpino, G., Bernardo, A., Martignetti, A., Criscitiello, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy214 · Cited by 110
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
Rocca, A., Farolfi, A., Bravaccini, S., Schirone, A., & Amadori, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.870555 · Cited by 117
Eggersmann, T. K., Degenhardt, T., Gluz, O., Wuerstlein, R., & Harbeck, N. (2019) · BioDrugs · doi:10.1007/s40259-019-00337-6 · Cited by 128
Watt, A. C. S., Cejas, P., DeCristo, M. J., Metzger, O., Lam, E. Y. N., Qiu, X., BrinJones, H., Kesten, N., Coulson, R. S., Font‐Tello, A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00135-y · Cited by 129
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 116
Cretella, D., Ravelli, A., Fumarola, C., La Monica, S., Digiacomo, G., Cavazzoni, A., Alfieri, R., Biondi, A., Generali, D., Bonelli, M., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0741-3 · Cited by 107
Bonelli, M. A., Digiacomo, G., Fumarola, C., Alfieri, R. R., Quaini, F., Falco, A., Madeddu, D., Monica, S. L., Cretella, D., Ravelli, A., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.05.003 · Cited by 108
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
Godoy-Ortíz, A., Sánchez‐Muñoz, A., Chica-Parrado, M. D. R., Álvarez, M., Ribelles, N., Rueda‐Domínguez, A., & Alba, E. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01124 · Cited by 120
Palbociclib in metastatic breast cancer: current evidence and real-life data
Serra, F., Lapidari, P., Quaquarini, E., Tagliaferri, B., Sottotetti, F., & Palumbo, R. (2019) · Drugs in Context · doi:10.7573/dic.212579 · Cited by 109
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Bonelli, M. A., Monica, S. L., Fumarola, C., & Alfieri, R. R. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113676 · Cited by 112
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1872 · Cited by 102
“The link between estrogen receptor (ER) signaling and G1–S phase cell-cycle progression has informed the combined use of CDK4/6 inhibitors with endocrine therapy (11).”
BackgroundMethodHuang, X., Di Liberto, M., Jayabalan, D., Liang, J., Ely, S., Bretz, J., Shaffer, A. L., Louie, T., Chen, I., Randolph, S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415984 · Cited by 102
Self-citationDifferential impact of RB status on E2F1 reprogramming in human cancer
McNair, C. M., Xu, K., Mandigo, A. C., Benelli, M., Leiby, B. E., Rodrigues, D. N., Lindberg, J., Grönberg, H., Crespo, M., Laere, B. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93566 · Cited by 114
Dieras, V. C., Rugo, H. S., Schnell, P., Gelmon, K. A., Cristofanilli, M., Loi, S., Colleoni, M. A., Lu, D. R., Mori, A., Gauthier, E. R., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy109 · Cited by 106
Chohan, T. A., Qayyum, A., Rehman, K., Tariq, M., & Akash, M. S. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.116 · Cited by 112
Breast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 112
Logan, J. E., Mostofizadeh, N., Desai, A. J., von Euw, E., Conklin, D. F., Konkankit, V., Hamidi, H., Eckardt, M. A., Anderson, L. A., Chen, H., et al. (2013) · PubMed · Cited by 111
Miettinen, T. P., Peltier, J., Härtlova, A., Gierliński, M., Jansen, V. M., Trost, M., & Björklund, M. (2018) · The EMBO Journal · doi:10.15252/embj.201798359 · Cited by 101
Angelis, C. D., Fu, X., Cataldo, M. L., Nardone, A., Pereira, R., Veeraraghavan, J., Nanda, S., Qin, L., Sethunath, V., Wang, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4191 · Cited by 109
Uzhachenko, R. V., Bharti, V., Ouyang, Z., Blevins, A., Mont, S., Saleh, N., Lawrence, H. A., Shen, C., Chen, S., Ayers, G. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108944 · Cited by 110
Turner, N. C., Finn, R. S., Martín, M., Im, S., DeMichele, A. M., Ettl, J., Dieras, V. C., Moulder, S., Lipatov, O. N., Colleoni, M. A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx797 · Cited by 100
Asghar, U. S., Kanani, R., Roylance, R. R., & Mittnacht, S. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00002 · Cited by 120
Tang, L. H., Contractor, T., Clausen, R., Klimstra, D. S., Du, Y. N., Allen, P. J., Brennan, M. F., Levine, A. J., & Harris, C. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3264 · Cited by 99
Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies
Xu, X., Pan, X., Wang, T., Wang, J., Yang, B., He, Q., & Ding, L. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0416-4 · Cited by 111
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers
Hydbring, P., Wang, Y., Fassl, A., Li, X., Matía, V., Otto, T., Choi, Y. J., Sweeney, K. E., Suski, J. M., Yin, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.004 · Cited by 101
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 110
Signaling pathways in breast cancer: Therapeutic targeting of the microenvironment
Kamdje, A. H. N., Etet, P. F. S., Vecchio, L., Jm, M., Krampera, M., & Lukong, K. E. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.07.034 · Cited by 112
Lysosomal trapping of palbociclib and its functional implications
Llanos, S., Megias, D., Blanco-Aparicio, C., Hernández-Encinas, E., Rovira, M., Pietrocola, F., & Serrano, M. (2019) · Oncogene · doi:10.1038/s41388-019-0695-8 · Cited by 96
Cyclin E as a potential therapeutic target in high grade serous ovarian cancer
Kanska, J. E., Zakhour, M., Taylor‐Harding, B., Karlan, B. Y., & Wiedemeyer, W. R. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.111 · Cited by 100
Ahlin, C., Lundgren, C., Varro, E. E., Jirström, K., BLOMQVIST, C. P., & Fjällskog, M.-L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4294-5 · Cited by 98
Witzleben, A. V., Goerttler, L. T., Marienfeld, R. B., Barth, H., Lechel, A., Mellert, K., Böhm, M., Kornmann, M., Mayer‐Steinacker, R., von Baer, A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3270 · Cited by 107
Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00124 · Cited by 94
Approaches to modernize the combination drug development paradigm
Day, D., & Siu, L. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0369-x · Cited by 104
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
Vijayaraghavan, S., Moulder, S., Keyomarsi, K., & Layman, R. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0541-2 · Cited by 99
Kim, S., Tiedt, R., Loo, A., Horn, T., Delach, S., Kovats, S., Haas, K., Engstler, B. S., Cao, A., Pinzon-Ortiz, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26215 · Cited by 93
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 95
Xi, J., Oza, A., Thomas, S. N., Ademuyiwa, F. O., Weilbaecher, K. N., Suresh, R., Bose, R., Cherian, M. A., Hernandez-Aya, L. F., Frith, A. E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7094 · Cited by 95
Johnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Schoninger, S., & Blain, S. W. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0253 · Cited by 95
Fassl, A., Brain, C. T., Abu-Remaileh, M., Stukan, I., Butter, D., Stępień, P., Feit, A. S., Bergholz, J. S., Michowski, W., Otto, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2210 · Cited by 102
Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
Tamura, K., Mukai, H., Naito, Y., Yonemori, K., Kodaira, M., Tanabe, Y., Yamamoto, N., Osera, S., Sasaki, M., Mori, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12932 · Cited by 92
Sonke, G. S., Hart, L. L., Campone, M., Erdkamp, F., Janni, W., Verma, S., Villanueva, C., Jakobsen, E. H., Alba, E., Wist, E., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4523-y · Cited by 92
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 102
Yuan, Y., Lee, J. S., Yost, S. E., Frankel, P. H., Ruel, C., Egelston, C. A., Guo, W., Padam, S., Tang, A., Martínez, N., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.035 · Cited by 97
Robinson, T., Liu, J. C., Vizeacoumar, F. S., Sun, T., MacLean, N., Egan, S. E., Schimmer, A. D., Datti, A., & Zacksenhaus, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078641 · Cited by 96
The Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
Michel, L., Ley, J. C., Wildes, T. M., Schaffer, A., Robinson, A., Chun, S., Lee, W., Lewis, J. S., Trinkaus, K. M., & Adkins, D. R. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.011 · Cited by 91
Lloyd, M. R., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2947 · Cited by 101
Al-Qasem, A. J., Alves, C. L., Ehmsen, S., Tuttolomondo, M., Terp, M. G., Johansen, L. E., Vever, H., Hoeg, L. V. A., Eliáš, D., Bak, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00311-6 · Cited by 103
Lamb, R., Lehn, S., Rogerson, L., Clarke, R. B., & Landberg, G. (2013) · Cell Cycle · doi:10.4161/cc.25403 · Cited by 95
Rugo, H. S., Turner, N. C., Finn, R. S., Joy, A. A., Verma, S., Harbeck, N., Masuda, N., Im, S., Huang, X., Kim, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.017 · Cited by 91
Dieras, V. C., Harbeck, N., Joy, A. A., Gelmon, K. A., Ettl, J., Verma, S., Lu, D. R., Gauthier, E. R., Schnell, P., Mori, A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0019 · Cited by 93
Katzenellenbogen, B. S., Guillen, V. S., & Katzenellenbogen, J. A. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01675-8 · Cited by 100
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Hernandez-Aya, L. F., & Ma, C. X. (2016) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2016.09.017 · Cited by 89
Cretella, D., Fumarola, C., Bonelli, M. A., Alfieri, R. R., Monica, S. L., Digiacomo, G., Cavazzoni, A., Galetti, M., Generali, D., & Petronini, P. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-49484-4 · Cited by 88
c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
Ji, W., Zhang, W., Wang, X., Shi, Y., Yang, F., Xie, H., Zhou, W., Wang, S., & Guan, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02980-2 · Cited by 94
CDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 91
Targeting the androgen receptor in triple-negative breast cancer
Gucalp, A., & Traina, T. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.004 · Cited by 98
de Gooijer, M. C., Zhang, P., Thota, N., Mayayo‐Peralta, I., Buil, L. C. M., Beijnen, J. H., & van Tellingen, O. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0266-y · Cited by 88
Sammons, S. L., Topping, D. L., & Blackwell, K. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170330120452 · Cited by 96
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Guarducci, C., Bonechi, M., Boccalini, G., Benelli, M., Risi, E., Leo, A. D., Malorni, L., & Migliaccio, I. (2017) · Breast Care · doi:10.1159/000484167 · Cited by 91
Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Kumarasamy, V., Vail, P., Nambiar, R., Witkiewicz, A. K., & Knudsen, E. S. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2275 · Cited by 86
Kalous, O., Conklin, D. F., Desai, A. J., O’Brien, N. A., Ginther, C., Anderson, L. A., Cohen, D. J., Britten, C. D., Taylor, I., Christensen, J. G., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0730 · Cited by 90
Vidula, N., & Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.07.005 · Cited by 96
Tap, W. D., Gong, K.-W., Daring, J., Tseng, Y., Ginther, C., Pauletti, G., Glaspy, J. A., Essner, R., Bollag, G., Hirth, P., et al. (2010) · Neoplasia · doi:10.1593/neo.10414 · Cited by 85
Spring, L. M., Bardia, A., & Modi, S. (2016) · PubMed · Cited by 105
Min, A., Kim, J. E., Kim, Y., Lim, J. M., Kim, S., Kim, J. W., Lee, K.-H., Kim, T., Oh, D., Bang, Y., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.037 · Cited by 99
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Scott, S. C., Lee, S. S., & Abraham, J. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.006 · Cited by 96
Alves, C. L., Ehmsen, S., Terp, M. G., Portman, N., Tuttolomondo, M., Gammelgaard, O. L., Hundebøl, M. F., Kaminska, K. K., Johansen, L. E., Bak, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25422-9 · Cited by 97
Li, Y., Luo, X., Guo, Q., Nie, Y., Wang, T., Zhang, C., Huang, Z., Wang, X., Liu, Y., Chen, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00209 · Cited by 88
HOTAIR , a long noncoding RNA , is a marker of abnormal cell cycle regulation in lung cancer
Liu, M., Zhang, H., Li, Y., Wang, R., Li, Y., Zhang, H., Ren, D., Liu, H., Kang, C., & Chen, J. (2018) · Cancer Science · doi:10.1111/cas.13745 · Cited by 96
Long, F., He, Y., Fu, H., Li, Y., Bao, X., Wang, Q., Wang, Y., Xie, C., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13957 · Cited by 87
MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6
Zhu, K., Liu, L., Zhang, J., Wang, Y., Liang, H., Fan, G., Jiang, Z., Zhang, C., Chen, X., & Zhou, G. (2016) · Protein & Cell · doi:10.1007/s13238-016-0277-2 · Cited by 83
Targeted therapies for ER+/HER2- metastatic breast cancer
Yamamoto‐Ibusuki, M., Arnedos, M., & André, F. (2015) · BMC Medicine · doi:10.1186/s12916-015-0369-5 · Cited by 95
Cell cycle dysregulation in cancer
Glaviano, A., Singh, S. K., Lee, E. H. C., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O’Connor, M. J., Koff, A., Singh, G., et al. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100030 · Cited by 110
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
The, I., Ruijtenberg, S., Bouchet, B. P., Cristobal, A., Prinsen, M. B. W., van Mourik, T., Koreth, J., Xu, H., Heck, A. J. R., Akhmanova, A. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms6906 · Cited by 86
Advances in Targeted Therapies for Triple-Negative Breast Cancer
McCann, K. E., Hurvitz, S. A., & McAndrew, N. P. (2019) · Drugs · doi:10.1007/s40265-019-01155-4 · Cited by 90
Zhou, J., Chen, Q., Zou, Y., Chen, H., Qi, L., & Chen, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00820 · Cited by 80
Payton, M. N., Belmontes, B., Hanestad, K., Moriguchi, J., Chen, K., McCarter, J. D., Chung, G., Ninniri, M. S. S., Sun, J., Manoukian, R., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00699-5 · Cited by 98
Qin, G., Xu, F., Qin, T., Zheng, Q., Shi, D., Xia, W., Tian, Y., Tang, Y., Wang, J., Xiao, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5993 · Cited by 81
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Lynce, F. C., Shajahan‐Haq, A. N., & Swain, S. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.008 · Cited by 85
Molecular Oncology of Breast Cancer
Joshi, H. N., & Press, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00022-2 · Cited by 97
Zeng, X., Shaikh, F. Y., Harrison, M. K., Adon, A. M., Trimboli, A. J., Carroll, K. A., Sharma, N., Timmers, C., Chodosh, L. A., Leone, G., et al. (2010) · Oncogene · doi:10.1038/onc.2010.253 · Cited by 78
Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer
Liu, J. C., Granieri, L., Shrestha, M., Wang, D., Vorobieva, I., Rubie, E. A., Jones, R. A., Ju, Y., Pellecchia, G., Jiang, Z., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.039 · Cited by 81
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Palmer, C. L., Boras, B. W., Pascual, B., Li, N., Li, D., Garza, S. J., Huser, N. H., Yuan, J. T., Cianfrogna, J. A., Sung, T., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.006 · Cited by 86
Rajput, S., Khera, N., Guo, Z., Hoog, J., Li, S., & Ma, C. X. (2016) · Oncotarget · doi:10.18632/oncotarget.10870 · Cited by 81
Im, S., Mukai, H., Park, I. H., Masuda, N., Shimizu, C., Kim, S.-B., Im, Y., Ohtani, S., Bartlett, C. H., Lu, D. R., et al. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00173 · Cited by 95
Ballinger, T. J., Meier, J. B., & Jansen, V. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00308 · Cited by 82
HER2-positive breast cancer is lost in translation: time for patient-centered research
Gingras, I., Gebhart, G., de Azambuja, E., & Piccart, M. J. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.96 · Cited by 78
CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
Iyengar, M., O’Hayer, P., Cole, A., Sebastian, T., Yang, K., Coffman, L., & Buckanovich, R. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24585 · Cited by 75
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Wu, X., Yang, X., Xiong, Y., Li, R., Ito, T., Ahmed, T. A., Karoulia, Z., Adamopoulos, C., Wang, H., Wang, L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00174-z · Cited by 85
Wang, Y., & Tang, S.-C. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10066-y · Cited by 70
Targeting Breast Cancer with CDK Inhibitors
Mayer, E. L. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0443-3 · Cited by 79
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 80
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma
Chen, Z., Wei Min, N. I., Li, J., Lin, S., Zhou, X., Sun, Y., Li, J. W., Leon, M. E., Hurtado, M. D., Zolotukhin, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.139497 · Cited by 78
Metadata
- Authors
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J.
- Affiliations
- University of California, Los Angeles (US)
- Pfizer (United States) (US)
- Corresponding author
- Finn, Richard S
- Venue
- Breast Cancer Research
- Published
- 2009-10-29
- Volume
- 11
- Issue
- 5
- Pages
- R77-R77
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC2790859
- OpenAlex
- W2148345265
- Cited by
- 1,398
- References
- 49
- Citations by year
- 2026: 48 · 2025: 76 · 2024: 64 · 2023: 94 · 2022: 115 · 2021: 121 · 2020: 137 · 2019: 128 · 2018: 137 · 2017: 131 · 2016: 105 · 2015: 92 · 2014: 51 · 2013: 42 · 2012: 28
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Russian Science Foundation
- National Institutes of Health (W81XWH)
- Jonsson Comprehensive Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- palbociclib, CDK4/6 inhibitors, HER2-amplified breast cancer, retinoblastoma protein phosphorylation, cyclin D1, CDKN2A, p16, G0/G1 cell cycle arrest, drug sensitivity, drug resistance, patient selection, breast cancer cell lines
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Cycle, Drug Synergism, Humans, Phosphorylation, Piperazines, Pyridines, Receptors, Estrogen, Tamoxifen, Retinoblastoma Protein, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling, Cell Line, Tumor, Cell Growth Processes, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.